Trials / Completed
CompletedNCT04008992
An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants
A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BMS-986259 in Healthy Participants.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A Randomized double blind, placebo controlled study of BMS-986259 to evaluate the safety and effectiveness of the drug amongst different conditions and populations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986259 | Single and Multiple ascending dose from Dose 1 to Dose 5 |
| OTHER | Placebo | Placebo matching BMS-986259 |
| DIAGNOSTIC_TEST | P-Aminohippurate | Diagnostic Agent |
| DIAGNOSTIC_TEST | Iohexol | Diagnostic Agent |
Timeline
- Start date
- 2019-06-18
- Primary completion
- 2021-01-04
- Completion
- 2021-01-04
- First posted
- 2019-07-05
- Last updated
- 2021-04-09
Locations
2 sites across 2 countries: Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT04008992. Inclusion in this directory is not an endorsement.